TITLE

Fine Chem Manufacturers To Strive for Critical Mass

AUTHOR(S)
Jarvis, Lisa
PUB. DATE
January 2001
SOURCE
Chemical Market Reporter;01/01/2001, Vol. 259 Issue 1, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the mergers and acquisitions (M&A) activity in the fine chemicals industry in the United States. What prompted mergers among pharmaceutical industry; Factors forcing some traditional chemical companies to withdraw from the pharmaceutical business; Fine chemical companies whose M&A is already underway.
ACCESSION #
3936895

 

Related Articles

  • INDIAN SCENE.  // Chemical Business;May2001, Vol. 15 Issue 5, p28 

    Presents news briefs on the Indian pharmaceutical and chemical sectors as of May 2001. Acquisition of the manufacturing facilities of Uniloids Ltd. by AVRA Laboratories; Expected market growth of the pharmaceutical industry; Rejection of the toll manufacturing agreement proposed by Pfizer Corp.

  • FTC, Department of Justice to Speed Antitrust Reviews.  // Chemical Week;3/13/2002, Vol. 164 Issue 11, p5 

    Reports the division of roles in federal reviews of proposed business mergers by the U.S. Federal Trade Commission (FTC) and the antitrust division of Department of Justice (DOJ). Authority of FTC on the chemical and pharmaceutical industries; Focus of DOJ on the high-technology and...

  • Fine Chemicals Producers Need to Look Beyond Size. Jarvis, Lisa // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p8 

    Focuses on the effects on fine chemicals producers of the productivity issues facing the pharmaceutical industry as of October 22, 2001. Problems forcing the pharmaceutical industry to reexamine its operating model; Views of consultant Peter Pollak on mergers and acquisitions in the...

  • Despite M&A, fine chems find niche. Mirasol, Feliza // Chemical Market Reporter;5/15/2006, Vol. 269 Issue 19, p34 

    The article looks at trends in the fine chemicals sector as of May 2006. The mergers of large branded and generic pharmaceutical companies have negatively affected fine chemical manufacturers because the combined companies have built their own manufacturing facilities. A chart showing the top...

  • Nepic will boost regional growth. O'Driscoll, Cath // European Chemical News;4/4/2005, Vol. 82 Issue 2141, p21 

    Reports on the merger of Pharmaceutical & Speciality Cluster of Great Britain and Teesside Chemical Initiative to form the North East Process Industry Cluster (Nepic) in April 2005. Traditions of the founding organisation of Nepic; Aim of the merger according to Stan Higgins, interim CEO of...

  • Avecia Acquires Carbohydrates-Based Chiral Technologies From Synthon Chiragenics.  // Chemical Market Reporter;2/24/2003, Vol. 263 Issue 8, p2 

    Reports on the acquisition of the pharmaceutical fine chemicals business of the New Jersey-based developer of chiral technologies, Synthon Chiragenics Corp. by the New Orleans, Louisiana-based company, Avecia Co. Details about the acquisition; Financial performance of the companies;...

  • Going global. Kovac, Matt; O'Driscoll, Cath // ICIS Chemical Business;7/31/2006, Vol. 1 Issue 30, p26 

    The article focuses on cross-border mergers and acquisitions by Indian chemical companies. In 2005, Indian companies made 103 cross-border acquisitions. This trend of overseas acquisitions is said to have been caused by India's competition with western nations in areas such as active ingredients...

  • A finequestion. Cerimele, Chris // ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p13 

    The article focuses on common concerns among outsourcers of fine chemicals, and how does merger and acquisition (M&A) activity relate to those issues. According to Contract Pharma's 2006 Annual Outsourcing Survey, the top five factors include quality, timeliness, confidentiality, good...

  • pharmaceuticals & fine chemicals.  // Chemical Week;11/21/2007, Vol. 169 Issue 38, p28 

    The article offers news briefs related to the pharmaceutical and chemical industries in the U.S. Cambrex will close its technical center in Brunswick, New Jersey and consolidate its U.S. research and development activities at the company's facility in Charles City, Iowa. Merck & Co. has agreed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics